Rabies Treatment Market Will Generate New Growth Opportunities by 2023 | MRFR
Research Reports
Jan 04, 2021
Market Outlook
The global rabies treatment market size is expected to exhibit a CAGR of 4.5% during the forecast period. Rabies normally occur in stray dogs which then spread the disease by biting the victim. Vaccination is one of the primary methods for treatment of rabies that can drive the market growth. One of the methods of preparing death by rabies is establishment of diagnosis clinics to take preventive actions as well administration of vaccination shots to relieve patients of their pain.
Rabies is a virus which is spread from the saliva of rabid/infected animals such as skunks, foxes, bats, cocoons, and coyotes. The global rabies treatment market report by Market Research Future (MRFR) has been compiled by research analysts with a thorough understanding of the disease as well as a close eye on the adverse effects and the various treatment methods currently available. Predictions for the period between 2017 and 2023 (forecast period) have been outlined in the form of drivers, trends, opportunities, and challenges.
Awareness campaigns by international organizations is projected to drive the global rabies treatment market growth. For instance, in 2015, International Organization for Animal Health (OIE), Food & Agriculture Organization (FAO), Global Alliance for Rabies Control (GARC), and WHO created a campaign to eliminate deaths caused by rabies by 2030. High production rate of contamination-free vaccines created via cell culture methods. Development of prophylactic vaccines despite the allocation of a small healthcare budget in numerous countries can turn the tide of losses in the market. The massive production rate of vaccines in culture-free media can influence the global rabies treatment market growth.
Competitive Outlook
VBI Vaccines Inc., Sanofi, Bio Med Pvt. Ltd., Pfizer, Taj Pharmaceuticals Limited, Merck & Co. Inc., Solvay, Bavarian Nordic, Informa plc., and CSC Pharmaceuticals International are prominent players operating in the global rabies treatment marketspace.
Segmentation Analysis
The global rabies treatment market is segmented by type, treatment, and end user.
By type, it is segmented into paralytic rabies, furious rabies, and others.
By treatment, it is segmented into brain tissue vaccine, rabies immunoglobin vaccine, tissue culture, and others.
End-users in the global rabies treatment market include epidemic prevention centers, clinics, hospitals, and others.
Request for Free Sample Report (85+ Pages with More Insight): https://www.marketresearchfuture.com/sample_request/1629
Regional Analysis
The Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA) are regions of focus which are being considered for the basis of the global rabies treatment market report.
The Americas had dominated the global market in 2016 and will continue their reign over the forecast period due to a plethora of research institutes for development of vaccines. Rabies vaccination drives in the region have contributed to the rabies treatment market.
Europe is the second biggest region after the Americas due to emphasis on governments for development of vaccines and ample funds for research and development. On the other hand, the MEA can register a sluggish growth rate due to lack of proper facilities and skilled personnel.
The APAC region can register the fastest growth rate during the forecast period due to wide penetration rate of rabies in China and India. Drives by governments to vaccinate stray dogs to cull the menace of the disease have been successful. Researchers in Australia have discovered the binding ability of the virus to prevent the STAT1 proteins to provide support in regions of its penetration. The new vaccine can target the virus directly and prevent it from binding necessary protein cells. All these factors can influence the growth of the rabies vaccine market.
Read Full Report Summary: https://www.marketresearchfuture.com/reports/rabies-treatment-market-1629
Industry News
A team formed at Thomas Jefferson University, Pennsylvania, have formed an inexpensive method to provide treatment to patients infected with rabies in 2019. It supplemented a protein cell in addition to the inactive virus and administered the shot with the number of antibodies spiking up to defend against the virus. It was successful on mice. Commercialization of the updated vaccine shots and awareness of the latest treatment method can be fruitful for the global rabies treatment market.
Tags:
, Reportedtimes, iCN Internal Distribution, Research Newswire, English